Skip to main content

Testing of a Tetravalent Dengue Vaccine in a Non-human Primate Model

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Award date: 
May 31, 2012
Award amount: 
$250,000
Organization name: 
Arbovax, Inc.
Principal Investigator: 
Thomas, Malcolm
Grant program category: 
Business Financing
Grant program name: 
Strategic Growth Loan
Region: 
Research Triangle

In order to produce a viable Dengue vaccine it must contain all four serotypes of the virus -- Dengue 1,2,3 and 4. Following the successful non-human primatetrials on their Dengue 2 vaccine candidates, Arbovax is in the process of producing stable deletion mutants of Dengue 1,3,and 4 that exhibit the required host-range characteristics. These four serotypes must them be put together to produce a tetravalent vaccine that balances out the immunogenicity of each individual component.
This is a pivotal trial for the company as it represents the ultimate proof of principle for the technology.

Fiscal year: 
2012